ClinicalTrials.gg
Enrolling by invitationNCT06938542FACE-RareUpdated Jan 28, 2026

Palliative Care Needs of Children With Rare Diseases and Their Families

An interventional study of Family Centered pediatric palliative care for family caregivers of children with rare diseases. in Trisomy 13 Syndrome, Arthrogryposis Congenita Multiplex With Intestinal Atresia and Asparagine Synthetase Deficiency, sponsored by Children's National Research Institute. Enrolling by invitation at 1 site in United States. Open to participants aged 12 Months to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-28.

Sponsored by Children's National Research Institute · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
480
Allocation
Randomized
Ages
12 Months to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Trisomy 13 Syndrome with a site in United States — 3 open to participants now, 3 under way, none of them phase 3. Trisomy 13 Syndrome · United States.

Started
2025
with 1 other
No phase
2 of 20
2 open now
Registered
19th of 20
by date
Lead sponsor
1 of 20
Children's National Research Institute

Among the 20 studies in Trisomy 13 Syndrome with a site in United States, this one is one of 2 that started in 2025, is one of 2 with no phase, and was the 19th registered.

Trisomy 13 Syndrome

26 studies on the registry are indexed under Trisomy 13 Syndrome; 3 are open to participants now.

Browse Trisomy 13 Syndrome studies →

Open to participants now

3 of the 20 studies in Trisomy 13 Syndrome with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 2 Trisomy 13 Syndrome studies recruiting now, 2 set no upper age limit and none stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 12 Months to 99 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Trisomy 13 Syndrome with a site in United States, or all of them as a file.
02

Study summary

The palliative care needs of family caregivers of children with rare diseases and their children are largely unmet, including the need for support to prepare for future medical decision making. This trial will test the FACE-Rare intervention to see if investigators can identify and meet those needs; and if FACE-Rare effects family caregivers' quality of life and child healthcare utilization. Finally, investigators will determine if the intersectionality of child-sex, family-race, Federal poverty level, and social connection influences family quality of life and child health care utilization longitudinally.

Read the detailed description

Pediatric patients with rare diseases experience high mortality with 30% not living to see their 5th birthday. Families are likely to be asked to make complex medical decisions for their child. Pediatric advance care planning involves preparation and skill development to help make future medical care choices. Children with rare disorders are a heterogeneous group, resulting in their exclusion from research. Available research on families of children with rare diseases lacks scientific rigor. Although desperately needed, there are few empirically validated interventions to address these issues. Investigators propose to close a gap in our knowledge of families' needs for support in a heterogeneous group of children with rare diseases; and to test an advance care planning intervention. The FAmily CEntered (FACE) pediatric advance care planning intervention is adapted to families with children who have rare diseases. Theoretically informed and developed and adapted by the principal investigator and key stakeholders, the proposed intervention will use Respecting Choices Next Steps Pediatric ACP™ for families whose child is unable to participate in health care decision-making. Our consultation with families of children with rare disorders and the National Organization for Rare Disorders (NORD) revealed that basic palliative care needs should be addressed first, prior to an advance care planning intervention. For the study to be able to meet this request, all families randomized to the intervention will first complete the Carer Support Needs Assessment Tool (CSNAT)© adapted by investigators for use in pediatrics. In the CSNAT Approach, facilitators assess caregivers' prioritized palliative care needs and develop Shared Action Plans for increasing informal social support. Thus, investigators propose an innovative 3-session FACE-Rare intervention, integrating two evidence-based approaches. Investigators will evaluate FACE-Rare using a scientifically rigorous intent-to-treat, assessor-blinded, longitudinal, prospective, three-site, randomized controlled trial design. Family/child triads (N=160) will be randomized to FACE-Rare (CSNAT Sessions 1 \& 2 plus Respecting Choices Sessions 3) or an enhanced information Treatment as Usual control group. All families will complete questionnaires at baseline and follow-up at 3-, 6- and 12 months. Investigators will evaluate the effect of FACE-Rare on family quality of life (caregiver appraisal, psychological, spiritual). Investigators will assess the palliative care needs of families at four time points. Investigators will determine the intersectionality of child-sex, family-race, and household income on family caregiver quality of life and child healthcare utilization. Investigators will explore the influence of urban vs. rural setting and religious coping on quality-of-life outcomes. Investigators will use advanced statistical methods informed by statistical advice from rare disease investigators for clinical trials in small populations.

03

Conditions studied

  • Trisomy 13 Syndrome
  • Arthrogryposis Congenita Multiplex With Intestinal Atresia
  • Asparagine Synthetase Deficiency
  • CHARGE Syndrome
  • Early Infantile Epileptic Encephalopathy
  • FOXG1 Syndrome
  • KBG Syndrome
  • Noonan Syndrome
  • Severe Hemophilia A
  • Short Bowel Syndrome
  • Beta-Propeller Protein-Associated Neurodegeneration
  • Brain Injury of Prematurity With Periventricular Leukomalacia
  • Chromosome 17p13.3 Microdeletion Syndrome
  • Chromosome 1q43-1q44 Deletion
  • Cockayne Syndrome
  • Congenital Diaphragmatic Hernia
  • End-Stage Renal Disease With Cloacal Anomaly
  • Mitochondrial Depletion Disorder
  • Severe Factor VII Deficiency

Keywords

  • pediatrics
  • palliative care
  • rare diseases
  • rare disorders
  • randomized clinical trial
  • advance care planning
  • quality of life
  • social connection
  • intervention
  • spirituality
  • anxiety
  • depression
  • caregiving
04

Who can participate

Ages eligible
12 Months to 99 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Child inclusion criteria:

  • ≥1.0 years and \<18.0 years at enrollment.
  • Unable to participate in end-of-life care decision-making.
  • Has a rare disease as operationally defined by NIH's Genetic and Rare Diseases Information Center (GARD).
  • Not under a Do Not Resuscitate Order or Allow a Natural Death Order.
  • Not in the Intensive Care Unit.

Family caregiver inclusion criteria:

  • > 18.0 years at enrollment.
  • Child's family caregiver/legal guardian.
  • Not known to be developmentally delayed.

Support person inclusion criteria:

  • > 18.0 years at enrollment.
  • Chosen by family caregiver.
  • Not known to be developmentally delayed.

Exclusion Criteria:

  • Family caregiver or support person is actively homicidal, suicidal, or psychotic at the time of enrollment.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
480 participants (estimated)

Study arms

  • Experimental
    FACE-Rare

    FACE-Rare (CSNAT-P Sessions 1 \& 2 plus Next Steps: Respecting Choices Sessions 3). The CSNAT-Pediatric intervention consists of two assessment visits with the facilitator, 2-8 weeks apart, comprising conversations about sources for support in a tertiary children's hospital. The adapted Next Steps: Respecting Choices pediatric Advance Care Planning conversation engages families in a process for how to make future medical decisions consistent with the families' goals and values. The Respecting Choices structured and facilitated conversation has five stages. Stage 1: Assesses the family's understanding of illness. Stage 2: Explores experiences with hospitalization. Stage 3: Explores goals of care. Stage 4: Creates an Advance Care Plan; Stage 5: Questions for providers are written down. Stage 6: Follow-up plan and referrals, as needed.

    Behavioral: Family Centered pediatric palliative care for family caregivers of children with rare diseases.

  • Experimental
    Enhanced Treatment As Usual (TAU)

    Treatment as Usual Control (TAU): To minimize the burden to families, we have chosen an enhanced (palliative care information and resources) TAU comparison condition.

    Behavioral: Family Centered pediatric palliative care for family caregivers of children with rare diseases.

Interventions

  • BehavioralFamily Centered pediatric palliative care for family caregivers of children with rare diseases.

    Child with rare disease who is unable to participate in medical decision making/family caregiver/support person triads will be randomized at a 1:1 ratio to one of two study arms, either the 3 session FACE-Rare intervention or the enhanced Treatment as Usual. Assessments will be completed at baseline, 3, 6 and 12 month outcomes.

06

What researchers measure

Primary outcomes

  1. Family Appraisal of Caregiving for Palliative Care (FACQ-PC)

    The FACQ-PC is a 25-item measure consists of four theoretically derived subscales: (i) caregiver strain, (ii) positive caregiving appraisals, (iii) caregiver distress, and (iv) family well-being. Scores are from 5 = strongly agree to 1 = strongly disagree. Investigators will not calculate a Total score. On the subscale scores for positive caregiving appraisals and family well-being, higher scores mean better outcomes, i.e. greater positive caregiving appraisals or family well-being. On the subscale scores for caregiver strain and caregiver distress, higher scores mean worse outcomes, i.e. greater caregiver strain or caregiver distress. The FACQ-PC subscale scores will be computed by taking the mean of the items (score range 1-5). Some items are reverse scored, depending on how the item is phrased, so that higher scores = higher amount of the subscale being measured. So the minimum value for each subscale is 1 and the maximum value for each subscale is 5.

    Time frame: Baseline, 3-, 6-, and 12 month post-intervention

  2. Functional Assessment of Chronic Illness Therapy-Spirituality-12 Version 4 Expanded (FACIT-Sp-EX)

    Assessed construct of spiritual well-being. Two subscales Meaning/Peace (7 items) and Faith (5 items) and Total score (12 items) were calculated. on a 5-point Likert scale from 0=not at all to 5=very much. Some items are reverse scored. See www.facit.org Meaning/Peace subscale score range from minimum value of 0 to maximum value of 32. Higher scores indicate better meaning/peace. Faith subscale score range from 0 minimum value to maximum value of 16. Higher scores indicate better meaning/peace. Total score range is from 0 minimum value to maximum value of 92. Higher scores indicate better spiritual well-being.

    Time frame: Baseline, 3-, 6-, and 12 month post-intervention

  3. Advance Care Plan for Child with Rare Disease Located in the Electronic Health Record (EHR).

    Documentation of an advance care plan for child with rare disease in the Electronic Health Record and decisional preference - to continue all treatments, to continue all treatments with exceptions noted, to provide comfort care only.

    Time frame: Baseline and 1 year

  4. Child Healthcare Utilization: initiation of palliative care consultations

    Using a standardized data abstraction form to count initiation of palliative care consultations during the study.

    Time frame: Baseline, 3-, 6-, 12-month.

  5. Generalized Anxiety Disorder-7 (GAD-7)

    Quality of life indicator with respect to emotional health-anxiety symptoms. 7 items. Higher scores indicate greater anxiety.

    Time frame: Baseline, 3-, 6-, 12-month

  6. Patient Health Questionaire-9 (PHQ-9)

    Quality of life indicator with respect to emotional health-depressive symptoms. 9 items. Higer scores indicate higher symptoms of depression. A yes response to question 9 (self-harm) will trigger a referral.

    Time frame: Baseline, 3-, 6-, 12-month

  7. Child Healthcare Utilization: # of days in palliative care before death.

    Using a standardized data abstraction form to count # of days in palliative care before death.

    Time frame: Baseline, 3-, 6-, 12-month

  8. Child Healthcare Utilization: # of hospitalizations during study participation

    Using a standardized data abstraction form to count # of days hospitalized during the study.

    Time frame: Baseline, 3-, 6-, 12-month

  9. Child Healthcare Utilization: # of Emergency Department visits during study participation

    Using a standardized data abstraction form to count # of days used Emergency Department during study.

    Time frame: Baseline, 3-, 6-, 12-month

  10. Child Healthcare Utilization: # of days in the Intensive Care Unit (ICU)

    Using a standardized data abstraction form to count # of days was admitted to ICU during the study.

    Time frame: Baseline, 3-, 6-, 12-month

  11. Child Healthcare Utilization: # of surgeries

    Using a standardized data abstraction form to count # of surgeries during the study.

    Time frame: Baseline, 3-, 6-, 12-month

Other outcomes

  1. Demographic Questionnaire

    Age of family caregiver, support person, and child.

    Time frame: Baseline

  2. Process Measure: Satisfaction Questionnaire

    Study specific process measure to assess adverse events and benefit/burden of participation. 13 items. Higher scores indicate greater satisfaction. Items are on a 5-point Likert scale from strongly disagree to strongly agree. 6 items were negative (felt afraid, too much to handle, harmful, angry, sad, hurtful) and 7 items were positive (useful, helpful, load off my mind, satisfied, something I needed to do, courageous, worthwhile). Each subscale is scored separately. Higher score for positive scale was better outcome. Higher score for negative scale was worse outcome.

    Time frame: Week 4

  3. Process Measure: Role Stress

    Visual analogue scale 0-100. "How stressful is it for you to make medical decisions for your child?" 1 item.

    Time frame: Baseline, 3-, 6-, 12-month

  4. Brief-Multidimensional Measure of Spirituality and Religion (Brief MMRS)

    Responses to 5 items from our previous research will be used to test moderator effects: "How often do you go to religious services? How often do you feel God's presence? how often do you pray privately? Do you identify as a religious person? Do you identify as a spiritual person?" Responses are on a 5 point likert scale. Higher scores indicated greater attendance at religious services, etc.

    Time frame: Baseline, 3-, 6-, 12-month

  5. BRICS (Brazil, Russia, India, China, South Africa) National Institute of Nursing Research (NINR) Social Determinants of Health (SDOH)

    NINR/National Institute of Health: "The SDOH are the conditions in which people are born, grow, live, work and age…." 32 items. Social connection score (how often, talk on telephone with family, friends, neighbors; get together; attend church or religious services; belong to clubs or organizations; marital partner status) and 2023 Federal Poverty Level for household income. Health insurance and housing insecurity will be used in secondary analysis.

    Time frame: Baseline, 3-, 6-, 12-month

  6. Health Resources and Services Administration (HRSA) Rural Health Grants Eligibility Analyzer

    Urban vs. rural setting. Address of participant is entered into the online analyzer, and it determines if this is a rural or urban setting which will be recorded in the data base.

    Time frame: Baseline, 3-, 6-, 12-month

  7. Carer Alert Thermometer (CAT)

    Measures child and family caregiver palliative care needs: The CAT is an evidence-based, comprehensive tool comprising 12 questions (broad areas of support need), used to identify two domains of unmet support needs, the current caring situation and the health and well-being of the caregiver. There is a traffic light scoring system so caregivers can rate their support need as green (low), amber (medium), and red (high) indicating level of need and potential risk each alert poses to the caregiving situation. Administered only to intervention participants.

    Time frame: Sessions 1 and 2 -- 2 and 3-4 weeks post baseline

  8. Demographic Questionnaire - Sex

    Sex of child, family caregiver and support person.

    Time frame: Baseline.

  9. Demographic Questionnaire - Race

    Race of child, family caregiver, and support person

    Time frame: Baseline.

  10. Demographic Questionnaire - Ethnicity

    Ethnicity of child, family caregiver, and support person.

    Time frame: Baseline.

  11. Demographic Questionnaire - Marital status.

    Marital status of family caregiver and support person.

    Time frame: Baseline.

  12. Demographic Questionnaire - Education.

    Education of family caregiver and support person.

    Time frame: Baseline.

  13. Demographic Questionnaire - Federal Poverty Level.

    Income above or below the 2025 Federal Poverty Level. Number of persons living in the household and household income will be collected to calculate these data.

    Time frame: Baseline.

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Feb 2029, 40 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2025
First posted
Apr 22, 2025
StartActual
Oct 2, 2025
Primary completionEst.
Feb 2, 2029
CompletionEst.
Aug 2, 2029
Last update
Jan 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06938542
Responsible party
Maureen Lyon (Clinical Psychologist, Tenured Professor of Pediatrics, Children's National Research Institute) — Principal investigator
First posted
Apr 22, 2025
Start date
Oct 2, 2025
Primary completion
Feb 2, 2029 (estimated)
Completion
Aug 2, 2029 (estimated)
Last update
Jan 28, 2026

Study contacts

Maureen E Lyon, PhD
principal investigator · Children's National Research Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion